Treatment with adjuvant endocrine therapy for early-stage breast cancer: Is it forever?

Journal of Clinical Oncology

Volumn 33, Issue 8, 2015, Pages 823-828

  Overmoyer, Beth ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE DENSITY; BREAST; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CASE REPORT; FEMALE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LUMBAR SPINE; MIDDLE AGED; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SENTINEL LYMPH NODE; VAGINA BLEEDING; BREAST NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 84924944021     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.2361     Document Type: Article

References (38)

1. Anderson WF, Chen BE, Jatoi I, et al: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100:121-126, 2006
2. Jatoi I, Anderson WF, Jeong JH, et al: Breast cancer adjuvant therapy: Time to consider its time-dependent effects. J Clin Oncol 29:2301-2304, 2011
3. Esserman LJ, Moore DH, Tsing PJ, et al: Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 129:607-616, 2011
4. Rakha EA, El-Sayed ME, Green AR, et al: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772-4778, 2007
5. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
6. Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patientlevel meta-analysis of randomised trials. Lancet 378:771-784, 2011
7. Stewart HJ, Prescott RJ, Forrest AP: Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst 93:456-462, 2001
8. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
9. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
10. Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
11. Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101-1108, 2011
12. Bliss JM, Kilburn LS, Coleman RE, et al: Disease-related outcomes with long-term follow-up: An updated analysis of the intergroup exemestane study. J Clin Oncol 30:709-717, 2012
13. Burstein HJ, Temin S, Anderson H, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255-2269, 2014
14. Jin H, Tu D, Zhao N, et al: Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA. 17 trial: Analyses adjusting for treatment crossover. J Clin Oncol 30: 718-721, 2012
15. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
16. Gray RG, Rea D, Handley K, et al: ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31:6s, 2013 (suppl 15s; abstr 5)
17. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005
18. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
19. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
20. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
21. Cardoso F, van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008
22. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al: Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 34:1-9, 2013
23. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728, 2008
24. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
25. Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783-2790, 2013
26. Gnant M, Filipits M, Greil R, et al: Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339-345, 2014
27. Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010
28. Filipits M, Rudas M, Jakesz R, et al: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors Clin Cancer Res 17:6012-6020, 2011
29. Jerevall PL, Ma XJ, Li H, et al: Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104:1762-1769, 2011
30. Zhang Y, Schnabel CA, Schroeder BE, et al: Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 19:4196-4205, 2013
31. Dubsky P, Brase J, Fisch K, et al: The Endo-Predict score identifies late distant metastases in ER+/HER2- breast cancer patients. Cancer Res 72, 2012 (suppl 24; abstr S4-3)
32. Sestak I, Cuzick J, Dowsett M, et al: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination (TransATAC) randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 33:916-922, 2015
33. Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278, 2011
34. Perez EA, Hurvitz SA, Amler LC, et al: Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: A randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res 16:R50, 2014
35. Polley MY, Leung SC, McShane LM, et al: An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897-1906, 2013
36. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006
37. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
38. Dixon JM, Renshaw L, Langridge C, et al: Anastrozole and letrozole: An investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat 125:741-749, 2011